Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.

CONCLUSION: Abnormal activation of EGFR may induce wtEGFR NSCLC cell resistance to cisplatin. The combined effects of cisplatin/gefitinib suggest that gefitinib, as a combination therapy for patients with cisplatin-resistant wtEGFR NSCLC should be considered.
PMID: 32342201 [PubMed - indexed for MEDLINE]

Source: Clinical Lung Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, Zhang R, Liu X, Zhou S, Wang R, Liu J, Tang X Tags: J Cancer Res Clin Oncol Source Type: research